Document Detail

Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients.
MedLine Citation:
PMID:  21047880     Owner:  NLM     Status:  In-Process    
PURPOSE: The associations between vitamin D and MRI measures of brain tissue injury have not been previously investigated in multiple sclerosis (MS). This research evaluates the significance of vitamin D and its active metabolites in brain tissue injury and clinical disability in MS patients.
METHODS: The study population consisted of 193 MS patients (152 women and 41 men; mean age 46.1 (SD 8.4) years; disease duration 13.8 (SD 8.4) years). Serum levels of 25-hydroxyvitamin D(3) (25(OH)VD(3)), 25-hydroxyvitamin D(2) (25(OH)VD(2)), 1α, 25-dihydroxyvitamin D(3) (1, 25(OH)(2)VD(3)) and 24(R), 25-dihydroxyvitamin D(3) (24, 25(OH)(2)VD(3)) were measured using a novel capillary liquid-chromatography-mass spectrometry method. Disability was assessed with the Expanded Disability Status Scale (EDSS) and the MS Severity Scale (MSSS). MRI measures included T2 lesion volume (LV), T1-LV and brain parenchymal fraction. The associations between deseasonalised levels of vitamin D metabolites and clinical and MRI measurements were assessed using regression analyses.
RESULTS: Lower deseasonalised levels of total 25(OH)VD (p=0.029), 25(OH)VD(3) (p=0.032) and 24, 25(OH)(2)VD(3) (p=0.005) were associated with higher MSSS. Similarly, lower deseasonalised levels of 24, 25(OH)(2)VD(3) (p=0.012) were associated with higher EDSS. Higher values of the 25(OH)VD(3) to 24, 25(OH)(2)VD(3) ratio were associated with higher MSSS (p=0.041) and lower brain parenchymal fraction (p=0.008).
CONCLUSIONS: Vitamin D metabolites have protective associations with disability and brain atrophy in MS. In particular, the results indicate strong associations for the 24, 25(OH)(2)VD(3) metabolite, which has not been extensively investigated in MS patients.
Bianca Weinstock-Guttman; Robert Zivadinov; Jun Qu; Diane Cookfair; Xiaotao Duan; Eunjin Bang; Niels Bergsland; Sara Hussein; Mariya Cherneva; Laura Willis; Mari Heininen-Brown; Murali Ramanathan
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2010-11-03
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  82     ISSN:  1468-330X     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  189-95     Citation Subset:  IM    
Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY 14260, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Comment In:
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):121   [PMID:  21148608 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Amygdalar enlargement in patients with temporal lobe epilepsy.
Next Document:  Grey matter atrophy of basal forebrain and hippocampus in mild cognitive impairment.